Litcius/Paper detail

Invalidation of geraniin as a potential inhibitor against SARS-CoV-2 main protease

Rui Zhang, Haohao Yan, Jiahao Zhou, Xiaoping Liu, Yunyu Chen

2023Natural Product Research14 citationsDOIOpen Access PDF

Abstract

Recently, geraniin has been identified as a potent antiviral agent targeting SARS-CoV-2 main protease (Mpro). Considering the potential of geraniin in COVID-19 treatment, a stringent validation for its Mpro inhibition is necessary. Herein, we rigorously evaluated the in vitro inhibitory effect of geraniin on Mpro using the fluorescence resonance energy transfer (FRET), fluorescence polarization (FP), and dimerization-dependent red fluorescent protein (ddRFP) assays. Our data indicate that geraniin is not a potential inhibitor against Mpro based on the results from a set of in vitro assays. These results suggest a stringent in vitro validation with diverse biochemical assays is essential for the discovery of Mpro inhibitors, and the fluorescence quenching effect caused by natural products should be considered when evaluating Mpro inhibitors.

Topics & Concepts

ProteaseVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ChemistryProtease inhibitor (pharmacology)Sars virusCoronavirus disease 2019 (COVID-19)BiologyBiochemistryMedicineEnzymeVirusViral loadInfectious disease (medical specialty)DiseasePathologyAntiretroviral therapyBee Products Chemical AnalysisEssential Oils and Antimicrobial ActivityPhytochemicals and Medicinal Plants
Invalidation of geraniin as a potential inhibitor against SARS-CoV-2 main protease | Litcius